Quinoline derivative MC1626, a putative GCN5 histone acetyltransferase (HAT) inhibitor, exhibits HAT-independent activity against Toxoplasma gondii.
We report that quinoline derivative MC1626, first described as an inhibitor of the histone acetyltransferase (HAT) GCN5, is active against the protozoan parasite Toxoplasma gondii in vitro. However, MC1626 does not inhibit Toxoplasma GCN5 HATs or reduce HAT-mediated activity; rather, this quinoline may target the plastid organelle called the apicoplast.
Smith
Aaron T
AT
Department of Pharmacology & Toxicology, IU Center For AIDS Research, Indiana University School of Medicine, 635 Barnhill Drive, MS A-525, Indianapolis, IN 46202, USA.
Livingston
Meredith R
MR
Mai
Antonello
A
Filetici
Patrizia
P
Queener
Sherry F
SF
Sullivan
William J
WJ
D000818:Animals; D000981:Antiprotozoal Agents; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D051548:Histone Acetyltransferases / Q000037:antagonists & inhibitors*; D015388:Organelles / Q000187:drug effects; D011804:Quinolines / Q000494:pharmacology*; D012441:Saccharomyces cerevisiae / Q000201:enzymology; D014122:Toxoplasma / Q000187:drug effects* / Q000201:enzymology*; D000099224:p300-CBP-Associated Factor
D000981:Antiprotozoal Agents; D004791:Enzyme Inhibitors; D051548:Histone Acetyltransferases; D011804:Quinolines; C504219:MC1626; C037219:quinoline; C501179:KAT2A protein, human; D000099224:p300-CBP-Associated Factor